Pharvaris (NASDAQ:PHVS) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Pharvaris (NASDAQ:PHVS) by 18.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 36,977 shares of the company’s stock after buying an additional 5,753 shares during the period. Geode Capital Management LLC’s holdings in Pharvaris were worth $685,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Novo Holdings A S boosted its stake in shares of Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after acquiring an additional 556,970 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in Pharvaris by 31.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after purchasing an additional 335,687 shares in the last quarter. Patient Square Capital LP acquired a new stake in Pharvaris during the 3rd quarter worth $4,488,000. State Street Corp acquired a new stake in Pharvaris during the 3rd quarter worth $1,000,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pharvaris during the third quarter worth $906,000.

Pharvaris Trading Down 4.0 %

NASDAQ:PHVS opened at $17.80 on Friday. The company has a market cap of $566.75 million, a P/E ratio of -6.36 and a beta of -3.06. Pharvaris has a twelve month low of $15.37 and a twelve month high of $33.00. The company’s 50-day moving average price is $20.12 and its 200-day moving average price is $19.35.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.